Dice CEO: Energy, T...
Antares Pharma Inc. (AIS: AMEX)
$2.76 0.04 | 1.47%
06/01/12 - 04:00 PM ET
Company Cash Flow
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -4.39M | -6.09M | -10.29M | -12.69M |
| Operating Gains/Losses | -30.00K | 56.90K | -70.51K | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -1.30M | 214.28K | -239.44K | -853.96K |
| (Increase) Decrease in Inventories | -629.51K | 57.09K | -147.52K | -56.63K |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 365.52K | -100.81K | -201.16K | 1.20M |
| (Decrease) Increase In Other Current Liabilities | 406.82K | 716.16K | -324.41K | -105.30K |
| (Increase) Decrease In Other Working Capital | 1.76M | -2.39M | 4.42M | -186.12K |
| Other Non-Cash Items | 1.87M | 1.31M | 1.19M | 1.16M |
| Net Cash From Continuing Operations | -1.93M | -6.08M | -5.10M | -10.32M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -1.93M | -6.08M | -5.10M | -10.32M |
| Sale of Property, Plant & Equipment | 30.00K | 29.10K | 175.00K | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 16.02M |
| Purchases of Property, Plant & Equipment | -581.80K | -212.01K | -187.58K | -1.56M |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -15.61M | -182.92K | -12.58K | 14.46M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 27.30M | 2.46M | 10.63M | 1.32M |
| Repayment of Long-Term Debt | 0.00 | 0.00 | -5.03M | -2.13M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | -233.29K | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 27.07M | 2.46M | 5.61M | -808.64K |
| Effect of Exchange Rate Changes | -25.96K | 87.59K | -31.87K | 12.14K |
| Net Change in Cash & Cash Equivalents | 9.51M | -3.71M | 462.79K | 3.34M |
Portfolios with AIS
- Portfolio NameUser Type
- Contributor5 Stocks Under-$10 Setting ...
- UserSMITTY
- Contributor8 Health Care Stocks With R...
- ContributorBreakout Stocks Of The Week...
- UserCurrent
- Userparvardigar
- Userhpats Portfolio 1
- Contributor11 Penny Stocks to Sell Now
- Userphospho
- UserTraderO4000 Portfolio 1
Latest AIS Headlines from TheStreet
- Antares Stock Hits New 52-Week High (AIS) 03.20.12 | 11:03 am
- Antares Pharma Inc. Stock Upgraded (AIS) 03.14.12 | 05:03 am
- Biotech Stock Live Chat: 2012 Preview 12.15.11 | 11:12 am
- Antares Stock Gaps Down On Today's Open (AIS) 12.15.11 | 09:12 am
- BioSante Pharma Readying Release of 'Female Viagra' Study Results 12.14.11 | 12:12 pm
- 5 Stocks Under $10 With Big Upside Potential 11.18.11 | 06:11 am
- 8 Health Care Stocks With Recent Gains 06.29.11 | 02:06 pm
- 4 Stocks Setting Up to Break Out 06.10.11 | 03:06 pm
- 11 Penny Stocks to Sell Now 07.20.10 | 11:07 am
- Hot Penny Stocks to Buy 06.14.10 | 11:06 am
Press Releases for AIS
- Antares Pharma To Present At The Jefferies Global Healthcare Conference - Business Wire 05.31.12 | 07:05 am
- Antares Pharma Reports First Quarter 2012 Financial And Operating Results - Business Wire 05.08.12 | 07:05 am
- Antares Pharma Announces Epinephrine Auto-Injector Settlement Agreement Between Teva And Pfizer - Business Wire 04.26.12 | 09:04 am
- Antares Pharma To Present At The 11th Annual Needham Healthcare Conference - Business Wire 03.28.12 | 07:03 am
- Antares Pharma Reports Fourth Quarter And Full Year 2011 Financial And Operating Results - Business Wire 03.12.12 | 07:03 am
- Antares Pharma To Host Fourth Quarter And Full Year 2011 Earnings Call - Business Wire 03.05.12 | 07:03 am
- Antares Pharma To Present At Upcoming Investor Conferences - Business Wire 02.29.12 | 07:02 am
- Antares Pharma Appoints John J. Howarth Vice President Of Corporate Affairs - Business Wire 02.27.12 | 09:02 am
- Antares Pharma Enters Licensing Agreement With Daewoong Pharmaceuticals Co. Ltd. For Oxybutynin Gel 3% In South Korea - Business Wire 01.17.12 | 08:01 am
- Antares Pharma Enters Licensing Agreement With Pfizer Consumer Healthcare - Business Wire 12.20.11 | 09:12 am
Partner Headlines for AIS
- Zacks #1 Rank Additions for Monday - Tale of the Tape - Zacks 05.14.12 | 09:05 am
- BioDelivery's Spike May Be A Short-Lived Downer - Seeking Alpha 04.04.12 | 08:04 am
- Why Antares Pharma Should Be On Your List For Long-Term Investment - Seeking Alpha 03.16.12 | 08:03 am
- Bio-Pharma Watch List: 2 Week Report Card - Seeking Alpha 03.12.12 | 09:03 am
- Earnings Expectations for the Week of March 12 (URBN, ROST) - Benzinga 03.11.12 | 11:03 am
- A Bio-Pharma Watch List For This Week: 4 Buys, 1 Sell - Seeking Alpha 02.22.12 | 09:02 am
- SIGA Could Be Ready For A Large Short-Term Pop - Seeking Alpha 01.15.12 | 09:01 am
- Antares Pharma's New Blockbuster Drug Has Potential To Generate Long-Term Revenue - Seeking Alpha 12.28.11 | 06:12 am
- Watson-Amgen to Develop Biosimilars - Analyst Blog - Zacks 12.20.11 | 10:12 am
- Q3 Micro-Cap Biotech Picks By The World's Largest Fund Managers - Seeking Alpha 12.08.11 | 09:12 am





